In Vitro Regio- and Stereoselective Oxidation of β-Ionone by Human Liver Microsomes

被引:3
作者
Marumoto, Shinsuke [1 ]
Shimizu, Ryoyu [2 ]
Tanabe, Genzoh [3 ]
Okuno, Yoshiharu [4 ]
Miyazawa, Mitsuo [2 ,5 ]
机构
[1] Kinki Kindai Univ, Joint Res Ctr, Higashiosaka, Osaka, Japan
[2] Kinki Kindai Univ, Fac Sci & Engn, Dept Appl Chem, Higashiosaka, Osaka 5778502, Japan
[3] Kinki Kindai Univ, Pharmaceut Res & Technol Inst, Higashiosaka, Osaka, Japan
[4] Wakayama Natl Coll Technol, Dept Mat Sci, Wakayama, Japan
[5] Nara Inst Sci & Technol, Grad Sch Mat Sci, Ikoma, Nara, Japan
关键词
beta-ionone; human liver microsome; cytochrome P450; regio- and stereoselective oxidation; 4-hydroxy-beta-ionone; HUMAN CYTOCHROME-P-450 ENZYMES; BUPROPION HYDROXYLATION; INTERINDIVIDUAL VARIABILITY; VOLATILE COMPOUNDS; METABOLISM; CYP2B6; P450; INHIBITION; EXPRESSION; IDENTIFICATION;
D O I
10.1055/s-0042-112128
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
The metabolism of the norisoprenoid beta-ionone was investigated in vitro using human liver microsomes and 11 different recombinant cytochrome P450 enzymes expressed in Trichoplusia ni cells. beta-Ionone was found to be oxidized via 4S-hydroxylation by CYP2B6 in human liver microsomes. CYP1A2 also regioselectively catalyzed the hydroxylation of beta-ionone to yield 4-hydroxylation; this conversion was not stereoselective. Further kinetic analysis revealed that CYP2B6 exhibited the highest activity for beta-ionone 4-hydroxylation. Kinetic analysis showed that K-m and V-max for oxidation of beta-ionone by CYP1A2 and CYP2B6 was 107.9 +/- 36.0 mu M and 3200.3 +/- 323.0 nmol/min/nmol P450 and 5.6 +/- 1.2 mu M and 572.8 +/- 29.8 nmol/min/nmol P450, respectively. The reaction rates observed using human liver microsomes and recombinant CYP2B6 were very high compared with those of other CYP2B6 substrates reported thus far. These results suggest that beta-ionone, a norisoprenoid present in nature, is one of the effective substrates for CYP2B enzymes in human liver microsomes. To the best of our knowledge, this is the first time that 4-hydroxy beta-ionone has been described as a human metabolite of beta-ionone.
引用
收藏
页码:292 / 299
页数:8
相关论文
共 35 条
[21]  
Khojasteh-Bakht SC, 1999, DRUG METAB DISPOS, V27, P574
[22]   Identification and characterization of potent CYP2B6 inhibitors in woohwangcheongsimwon suspension, an herbal preparation used in the treatment and prevention of apoplexy in Korea and China [J].
Kim, Hyunmi ;
Kim, Kwon-Bok ;
Ku, Hei-Young ;
Park, Soo Jin ;
Choi, Hoon ;
Moon, Joon-Kwan ;
Park, Byeoung-Soo ;
Kim, Jeong-Han ;
Yea, Sung Su ;
Lee, Choong-Hwan ;
Lee, Hye Suk ;
Shin, Jae-Gook ;
Liu, Kwang-Hyeon .
DRUG METABOLISM AND DISPOSITION, 2008, 36 (06) :1010-1015
[23]   Changes in volatile compounds of carrots (Daucus carota L.) during refrigerated and frozen storage [J].
Kjeldsen, F ;
Christensen, LP ;
Edelenbos, M .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2003, 51 (18) :5400-5407
[24]   Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes [J].
Miyazawa, M ;
Shindo, M ;
Shimada, T .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (05) :602-607
[25]  
Miyazawa M, 2001, DRUG METAB DISPOS, V29, P200
[26]   Metabolism of (+)-fenchone by CYP2A6 and CYP2136 in human liver microsomes [J].
Miyazawa, Mitsuo ;
Gyoubu, Kunihiko .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2006, 29 (12) :2354-2358
[27]   Facile lipase catalysed syntheses of (S)-(+)-4-hydroxy-β-ionone and (S)-(+)-4-hydroxy-β-damascone: chiral flavorants and synthons [J].
More, Gauri P. ;
Bhat, Sujata V. .
TETRAHEDRON LETTERS, 2013, 54 (32) :4148-4149
[28]  
Nakajima M, 2001, DRUG METAB DISPOS, V29, P1110
[29]   THE P450 SUPERFAMILY - UPDATE ON NEW SEQUENCES, GENE-MAPPING, ACCESSION NUMBERS, EARLY TRIVIAL NAMES OF ENZYMES, AND NOMENCLATURE [J].
NELSON, DR ;
KAMATAKI, T ;
WAXMAN, DJ ;
GUENGERICH, FP ;
ESTABROOK, RW ;
FEYEREISEN, R ;
GONZALEZ, FJ ;
COON, MJ ;
GUNSALUS, IC ;
GOTOH, O ;
OKUDA, K ;
NEBERT, DW .
DNA AND CELL BIOLOGY, 1993, 12 (01) :1-51
[30]   Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals [J].
Rotger, M. ;
Tegude, H. ;
Colombo, S. ;
Cavassini, M. ;
Furrer, H. ;
Decosterd, L. ;
Blievernicht, J. ;
Saussele, T. ;
Guenthard, H. F. ;
Schwab, M. ;
Eichelbaum, M. ;
Telenti, A. ;
Zanger, U. M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (04) :557-566